<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Oyindamola Adetokunbo on Medium]]></title>
        <description><![CDATA[Stories by Oyindamola Adetokunbo on Medium]]></description>
        <link>https://medium.com/@oyinadetokunbo?source=rss-40deeaafab8f------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*H69Pz-hBYS4bQFSnh-va2g@2x.jpeg</url>
            <title>Stories by Oyindamola Adetokunbo on Medium</title>
            <link>https://medium.com/@oyinadetokunbo?source=rss-40deeaafab8f------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 23:31:27 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@oyinadetokunbo/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Tuberculosis Risks Detection and Treatment in Human Populations]]></title>
            <link>https://medium.com/@oyinadetokunbo/tuberculosis-risks-detection-and-treatment-in-human-populations-8b7c03c6ab71?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/8b7c03c6ab71</guid>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[tuberculosis]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Tue, 24 Mar 2026 16:52:32 GMT</pubDate>
            <atom:updated>2026-03-24T21:57:39.277Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*j5UmmrzyK9QTxxCoFFU6dw.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/portfolio/Fani12?mediatype=photography"><em>Fania Witardiana</em></a><em> on </em><a href="https://www.istockphoto.com/"><em>iStock</em></a></figcaption></figure><h3><strong>It takes knowledge of the disease, recognition of symptoms, and timely intervention to effectively prevent the spread of tuberculosis.</strong></h3><p>According to the <a href="https://www.who.int/publications/i/item/9789240116924">WHO Global Tuberculosis Report 2025</a>, more than 10.7 million people contract tuberculosis every year, and approximately 1.23 million die from the disease. These numbers represent far more than statistics. They reflect human lives lost and families profoundly affected by an illness that is both preventable and treatable.</p><p>Tuberculosis(TB) remains one of the most lethal infectious diseases globally. Although progress has been made, particularly after the disruptions caused by the COVID‑19 pandemic, the recent global decline in TB cases between 2023 and 2024 has been modest and uneven. This reduction alone is insufficient to eliminate the disease.</p><p>Tuberculosis is not o a human health issue. It also involves interactions with animals and the environment. Certain strains, such as those caused by <em>Mycobacterium bovis</em>, can be transmitted from cattle to humans. High population density, poor ventilation, and close contact with infected animals amplify the risk of infection. Recognizing these links is essential for effective TB control and the prevention of new outbreaks.</p><h3><strong>The Importance of Early Diagnosis</strong></h3><p>Active tuberculosis can spread through airborne droplets when an infected individual coughs, sneezes, or speaks. One untreated person can infect numerous others in close proximity.</p><p>Delayed diagnosis remains a major obstacle in controlling TB. Symptoms such as persistent cough, fever, weight loss, night sweats, and fatigue are often misattributed to other illnesses or everyday fatigue. This delay allows TB to spread silently in households, workplaces, and public spaces before it is detected.</p><p>Research indicates that in some regions, more than 20% of new TB cases are not identified promptly. Early medical evaluation and testing are therefore critical not only for the individual’s health but also for preventing broader transmission.</p><h3><strong>Populations at Increased Risk</strong></h3><p>While TB can affect anyone, certain groups are more vulnerable:</p><ul><li>Individuals with weakened immune systems, including people living with HIV or chronic medical conditions.</li><li>Close contacts of individuals diagnosed with TB.</li><li>Children and older adults, who are more likely to develop severe symptoms and progress rapidly from infection to active disease.</li></ul><p>Understanding these high-risk groups enables healthcare providers and communities to prioritize preventive care, targeted testing, and early interventions.</p><h3><strong>Treatment Protocols and Recovery Outcomes</strong></h3><p>Quick initiation of treatment following diagnosis is important for recovery and preventing transmission. Current antibiotic regimens are highly effective, and individuals who complete treatment fully can be cured and cease to be contagious.</p><p>Standard treatment usually involves a combination of antibiotics administered daily for 4 to 6 months under medical supervision. Adherence to the complete course is very important. Interrupting treatment can allow the bacteria to survive, potentially leading to ongoing infection and further spread.</p><h3>Overcoming Barriers to Care</h3><p>Access to care is often hindered by social, economic, and cultural factors. Stigma, high costs, and limited healthcare availability can discourage people from seeking medical evaluation.</p><p>Addressing these barriers is equally important as providing medical treatment. Supporting testing, providing education about TB, and creating accessible healthcare services reduce delays and prevent further transmission of the disease.</p><h3><strong>Individual and Community Actions</strong></h3><p>Individuals can play an active role in TB prevention and control:</p><ul><li>Individuals with symptoms such as persistent cough, fever, night sweats, or unexplained weight loss should seek medical attention immediately.</li><li>Encourage testing for anyone who may have been exposed.</li><li>Share accurate information about TB to reduce stigma and fear.</li></ul><p>It is important to understand that timely diagnosis, adherence to treatment, and community awareness are fundamental to controlling TB. Likewise, knowledge, proactive healthcare, and social support collectively reduce the impact of the disease.</p><h3><strong>Strategies for Effective Management</strong></h3><p>Tuberculosis is both preventable and curable. Effective tools, treatments, and knowledge are available to fight against this disease. Early detection, completing treatment, and promoting informed communities are essential strategies to save lives and protect public health. Collective awareness and timely action provide the most reliable means of stopping the spread of tuberculosis and protecting future generations.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8b7c03c6ab71" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Antibiotic Resistance Is Independent of Treatment Duration]]></title>
            <link>https://medium.com/@oyinadetokunbo/antibiotic-resistance-is-independent-of-treatment-duration-42ab1fb14f97?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/42ab1fb14f97</guid>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Mon, 23 Mar 2026 17:36:17 GMT</pubDate>
            <atom:updated>2026-03-23T17:36:17.480Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*voD6bGU2RSKVsSzEOXJ95Q.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/portfolio/dikushin?mediatype=photography"><em>dikushin</em></a><em> on </em><a href="https://www.istockphoto.com/"><em>iStock</em></a></figcaption></figure><h3><strong>It is common to confuse antibiotic treatment length with resistance risk.</strong></h3><p>Many people assume that longer antibiotic treatments automatically lead to bacterial resistance. This belief is understandable, given widespread discussions about antibiotic resistance. It seems intuitive that extended exposure would allow bacteria to evolve stronger defenses.</p><p>However, the development of resistance is more complex. Resistance does not occur merely because a course of antibiotics is prolonged. Instead, it develops when bacteria survive antibiotic exposure under specific conditions. These conditions are generally associated with how antibiotics are administered, not only the duration of treatment.</p><h3><strong>Underlying Causes of Misperceptions Regarding Antibiotic Use</strong></h3><p>A prevalent misconception is that extended antibiotic courses directly cause resistance. Rising rates of resistant infections worldwide reinforce this assumption. Seeing increase in resistance often leads people to conclude that all aspects of antibiotic use contribute equally to the problem.</p><p>That assumption overlooks how resistance actually develops in bacteria. In reality, resistance develops primarily when:</p><ul><li>Antibiotics are used unnecessarily</li><li>Treatments are discontinued early</li><li>Incorrect doses are taken or administered</li><li>Antibiotics are reused or shared without medical supervision</li></ul><p>These practices allow some bacteria to survive in environments that promote adaptation. The bacteria that persist are typically those most capable of resisting future treatments.</p><p>In contrast, an appropriately prescribed extended antibiotic course is intended to completely eradicate the infection. If a doctor determines that a longer course is necessary, the goal is to remove harmful bacteria entirely so they cannot return or adapt.</p><h3><strong>Evidence-Based Clinical Guidelines</strong></h3><p>Recent guidance from global health organizations emphasizes the correct use of antibiotics instead of focusing solely on treatment duration. Current clinical recommendations include:</p><ul><li>Prescribing antibiotics only when medically justified</li><li>Customizing antibiotic type and duration to the specific infection</li><li>Monitoring patient response to adjust treatment as needed</li><li>Minimizing unnecessary antibiotic exposure</li></ul><p>These recommendations reflect a comprehensive understanding of how resistance develops and how that antibiotic can be used without losing effectiveness.</p><h3><strong>Antibiotic Resistance as a Global Concern</strong></h3><p>Antibiotic resistance is a growing challenge worldwide. Between 2018 and 2023, resistance increased in over 40% of studied bacteria-antibiotic combinations. Resistance is not solely a result of individual behavior but comes from interconnected factors involving human, animal, and environmental health.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*BfDkCRw9h7v3dwAK9OAN0Q.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/portfolio/urzine?mediatype=photography"><em>Urzine</em></a><em> on </em><a href="https://www.istockphoto.com/"><em>iStock</em></a></figcaption></figure><p>Antibiotics are used across hospitals, communities, and agriculture, and resistant bacteria can circulate between humans, animals, soil, and water. Addressing resistance requires coordinated action across all these sectors. Misuse in any context contributes to the global burden of resistance.</p><p>Public health campaigns increasingly emphasize that resistance is influenced by patterns of antibiotic use, not simply by the length of individual treatment courses.</p><h3>Implications for Patients</h3><p>What this means for someone taking antibiotics is that, to prevent resistance:</p><ul><li>Use antibiotics only under the guidance of a qualified healthcare professional</li><li>Follow strictly the prescribed dosage and duration</li><li>Do not stop treatment early without medical advice</li><li>Do not extend the course independently</li><li>Do not reuse leftover antibiotics</li></ul><p>These practices reduce the likelihood of bacterial survival under suboptimal conditions and help maintain the long-term efficacy of antibiotics.</p><h3><strong>Integrating Understanding of Antibiotic Use</strong></h3><p>Resistance is determined by how antibiotics are used rather than the duration of use. Proper use ensures that:</p><ul><li>Pathogenic bacteria are fully eliminated</li><li>Opportunities for bacterial adaptation are minimized</li><li>Antibiotics remain effective for future patients</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*tMkPrkoYhJB2KdKJYTt2Gg.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/portfolio/bfk1992?mediatype=photography"><em>bfk92</em></a><em> on </em><a href="https://www.istockphoto.com/"><em>iStock</em></a></figcaption></figure><p>Improper use, on the other hand, allows bacteria to survive, adapt, and become more difficult to treat. Understanding this distinction is crucial. Treatment duration is only one element and is often secondary to correct administration.</p><h3><strong>Preserving Antibiotic Efficacy Through Responsible Use</strong></h3><p>Extended antibiotic courses do not inherently cause resistance. The primary factor is inappropriate use. Evidence-based, responsible antibiotic administration is essential to maintaining their effectiveness.</p><p>Changing the focus from duration alone to the broader context of proper use clarifies misconceptions and provides a more accurate understanding of resistance. Ensuring antibiotics are used correctly is the most effective strategy to protect both individual and public health.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=42ab1fb14f97" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[You Know It Is Not The End Yet]]></title>
            <link>https://medium.com/@oyinadetokunbo/you-know-it-is-not-the-end-yet-f0f782ceddd7?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/f0f782ceddd7</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[personal-growth]]></category>
            <category><![CDATA[education]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Fri, 09 Jan 2026 10:15:05 GMT</pubDate>
            <atom:updated>2026-01-09T11:25:34.034Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/848/1*yTXIjl3uFpEXCZpv1tArvA.png" /></figure><h3><strong>Starting is how clarity comes, even when it feels uncertain.</strong></h3><p>Writing 100 blogs in 100 days about One Health started as a random challenge. You know, one of those things you pick up because it sounds interesting at the time. I was curious. I wanted to understand how human health, animal health, and the environment were connected. I thought I would learn a few things, write a few posts, and move on.</p><p>I had every reason not to start. I mean, on the very first day, I had no clear idea how to approach the topics. I even wondered if I was biting off more than I could chew. But I still was excited to write and put something out there. Writing each blog felt like I was uncovering something new, something that mattered. It felt like I had found a lane where learning and writing about it met in a good way.</p><p>Yet, less than 10 days in, that feeling started to change. Somewhere in between, the excitement from the first few days had faded into a mix of pressure and uncertainty. I was getting overwhelmed.</p><p>Some days I would just stare, exhausted.<br>Not because there was nothing to write about, but because there was too much to wrap my head around. The more I learned about One Health, the wider it became. It was no longer just about diseases or animals or the environment. It was about how we live, what we eat, how we treat the land, and how our choices ripple farther than we think.</p><p>It started to feel heavy to keep writing.<br>Don’t get me wrong.<br>Not heavy in a bad way, but in a real way. The kind of weight that comes when you realize you are dealing with something that actually matters. I had days when I wondered why I even started. Days when reaching the number 100 felt like a distant, almost impossible goal</p><p>And yet, I kept going.</p><p>But here is the thing.<br>Right when I was getting close to the end, I felt like I was just beginning to understand what One Health really meant. There were still so many things to write about. So many topics to explore. It felt strange to be nearing the finish line and still feel like I had not said enough.</p><p>That was when it occurred to me.<br>&quot;This is how life works.&quot;</p><p>We start things with excitement.<br>We move through confusion.<br>We reach a point where we want to stop.<br>And then, just when we think we are done, we see how much more there is.</p><p>One Health did not just teach me about health.<br>It taught me about staying with something even when it feels unclear. It taught me that you do not need to have everything figured out to keep moving. You just need to keep showing up.</p><p>Trust me, I still do not have all the answers.<br>But I do have a huge respect for how connected everything is. Our bodies. Our food. Our animals. Our air. Our choices. Nothing stands alone.</p><p>And maybe that is the real gift of this challenge.<br>Not that I wrote 100 blogs in 100 days, but that I learned how to keep learning, even when it feels messy.</p><p>So if you are reading this and you have something you keep putting off, maybe this is your moment.</p><p>Not because you suddenly have time.<br>Not because you finally feel ready. (I never was ready. I picked this challenge at random).<br>But because starting is how clarity comes.</p><p>You do not need to see the whole path.<br>You just need to take the next step.</p><p>Write the first page.<br>Start the project.<br>Have the conversation.<br>Learn the thing that keeps pulling at you.</p><p>Let it be imperfect.<br>Let it be slow.<br>Let it change as you go.</p><p>That is how this One Health journey started for me.<br>And that is how most things that matter begin.</p><p>You do not have to have it all figured out.<br>You just have to start.</p><p>I’m rooting for you.❤️</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f0f782ceddd7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Emerging Priorities in One Health Research and Practice]]></title>
            <link>https://medium.com/@oyinadetokunbo/emerging-priorities-in-one-health-research-and-practice-845d3340a421?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/845d3340a421</guid>
            <category><![CDATA[health-innovation]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[health-equity]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Thu, 08 Jan 2026 08:41:23 GMT</pubDate>
            <atom:updated>2026-01-08T08:41:23.792Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*aRjdBply-Dfpp6lXVnoaYA.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/photo/global-healthcare-gm637207652-113535389"><em>Shansekala</em></a><em> on iStock</em></figcaption></figure><p><strong>The emphasis has moved toward implementation equity and measurable outcomes.</strong></p><p>The approach of One Health has reached a point of conceptual maturity. The interdependence of human, animal, and environmental health is now widely accepted across scientific and policy communities. So, the central concern today is no longer justification but execution, such that attention has changed toward examining how this integration is implemented, which priorities receive sustained investment, and how existing approaches must adapt to emerging global risks. To be exact, One Health has moved beyond a unifying idea and is increasingly evaluated by its practical outcomes.</p><p>Recent international reports and policy developments shows that One Health has become a central component of global health strategy, which is now embedded within funding priorities, research agendas, and national health planning processes. This change reflects a growing expectation that One Health principles should translate into measurable improvements in prevention, preparedness, and response.</p><h3><strong>Institutionalization of Integrated Health Systems</strong></h3><p>One of the most significant developments in recent years has been the movement from advocacy to formal implementation. Under the Quadripartite collaboration, global institutions have encouraged countries to establish coordination mechanisms that connect public health services, veterinary systems, environmental authorities, and food production sectors.</p><p>This development addresses long standing fragmentation that has hindered timely detection and response to health threats. Current One Health practice therefore prioritizes shared surveillance structures, coordinated risk assessment processes, and unified response planning. Instead of operating as parallel structures, these sectors are increasingly embedded within national health security frameworks.</p><p>For the research community, this transition has practical implications. There is growing demand for evidence that evaluates how integrated systems function in diverse political, economic, and social contexts. Implementation focused research has become central, changing attention from defining One Health to assessing its effectiveness in practice.</p><h3><strong>Antimicrobial Resistance as a Central Policy and Research Focus</strong></h3><p>Antimicrobial resistance represents one of the clearest demonstrations of the interconnected nature of health systems. Patterns of antimicrobial use in human medicine, animal production, and environmental management contribute collectively to the spread of resistance. Recent global negotiations and national action plans reflect heightened urgency to address this issue through coordinated strategies.</p><p>Research priorities now extend beyond surveillance of resistance trends. Increasing emphasis is placed on understanding transmission pathways across sectors, evaluating stewardship interventions, and identifying alternatives to routine antimicrobial use in agriculture. Environmental dimensions of resistance have gained particular attention, as wastewater, soil, and surface water are recognized as critical reservoirs.</p><h3><strong>Advancements in Integrated Surveillance and Early Warning Systems</strong></h3><p>Zoonotic diseases remain a foundational concern within One Health research. However, contemporary efforts place greater emphasis on early detection through integrated surveillance. Advances in data integration have transformed how risks are identified and monitored.</p><p>Health authorities and research institutions are investing in systems that connect clinical data, animal health reporting, and environmental monitoring. Wastewater surveillance has expanded in scope and is increasingly explored as an early warning mechanism for both human and animal health threats.</p><p>Experience from recent outbreaks underscores the importance of timely detection. Research that strengthens data sharing frameworks, improves interoperability, and enhances local reporting capacity is now considered essential to effective One Health practice.</p><h3><strong>Climate Change as a Determinant of Health Risk</strong></h3><p>Climate change is no longer treated as a contextual factor in health research. It is increasingly understood as a direct determinant of disease emergence, food system stability, and patterns of human animal interaction. Changes in temperature, precipitation, and land use are reshaping exposure pathways and altering disease dynamics.</p><p>One Health research has responded by examining how environmental change influences health risk across systems. The expansion of vector borne diseases into new regions and the vulnerability of food systems under climate stress illustrate these interconnected effects.</p><p>Policy discussions have reinforced the need to align climate adaptation strategies with public health planning. This alignment has created opportunities for research that links ecosystem protection, biodiversity conservation, and disease prevention. The environment is now viewed as an active component of health systems rather than a passive setting.</p><h3><strong>Community Engagement and Equity in One Health Practice</strong></h3><p>Equity and local capacity have emerged as defining considerations in contemporary One Health frameworks. Effective surveillance and prevention often depend on individuals and institutions operating closest to the point of risk.</p><p>Community health workers, farmers, local veterinarians, and environmental officers are frequently the first to observe emerging threats. Research that excludes these perspectives risks overlooking critical knowledge. As a result, participatory research approaches are increasingly adopted, involving communities in data generation, interpretation, and response planning.</p><h3><strong>The Role of Technology in Supporting Integration</strong></h3><p>Technological innovation plays an important role in the future of One Health, but its value lies in supporting coordination rather than functioning as an independent solution. Developments in data analytics, genomic sequencing, and digital reporting have improved the ability to connect information across sectors.</p><p>Recent research emphasizes usability and accessibility. Tools must function effectively in resource constrained settings and support decision making at multiple levels. There is growing recognition that data alone does not improve outcomes without clear governance structures and collaborative processes.</p><h3><strong>Implications for Research and Professional Practice</strong></h3><p>The direction of One Health research and practice has become increasingly explicit. Integration is expected to be operational, measurable, and sustained over time. Studies confined to a single sector are increasingly regarded as insufficient for addressing complex health challenges.</p><p>Researchers are expected to engage with policy environments, recognize operational constraints, and communicate findings in ways that support action. Practitioners are likewise encouraged to work across disciplinary boundaries and adapt to governance systems that emphasize shared responsibility.</p><p>One Health has entered a phase in which credibility is closely tied to demonstrable outcomes. Prevention, resilience, and equity have become central benchmarks, informed by lessons from recent global health crises.</p><h3><strong>Future Outlook for One Health Integration</strong></h3><p>Now, One Health is defined less by theoretical alignment and more by its application in real world settings. Its development is influenced by antimicrobial resistance, climate related health risks, zoonotic disease emergence, and the demand for timely detection. Equally important are the people, institutions, and decisions that determine how integration is achieved in practice.</p><p>The continued relevance of One Health research depends on its ability to remain grounded in practical challenges while maintaining methodological rigor. Its long term success will rely on sustained collaboration, institutional trust, and a willingness to move beyond sectoral boundaries. In essence, the impact of One Health will increasingly be judged by its capacity to protect human well being, support livelihoods, and sustain ecosystems through coordinated and evidence informed action.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=845d3340a421" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Measles-Rubella Vaccination Strategies and Implementation in Nigeria]]></title>
            <link>https://medium.com/@oyinadetokunbo/measles-rubella-vaccination-strategies-and-implementation-in-nigeria-a0b58caa82ca?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/a0b58caa82ca</guid>
            <category><![CDATA[measles]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[measles-rubella-vaccine]]></category>
            <category><![CDATA[one-health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Wed, 07 Jan 2026 18:43:21 GMT</pubDate>
            <atom:updated>2026-01-07T19:26:06.807Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*gGhInN0142YzynleFPsiAA.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/photo/measles-vaccine-bottle-gm2226625377-642563216"><em>koto_feja</em></a><em> on iStock</em></figcaption></figure><h3><strong>Vaccination and immunisation efforts are central to eliminating measles-rubella by 2030.</strong></h3><p>Despite the availability of highly effective vaccines, measles and rubella remain significant public health concerns worldwide. Recent outbreaks in several regions show how quickly these diseases can resurface when vaccination coverage declines. Between 2025 and 2026, these realities informed large-scale public health interventions in Nigeria, including integrated vaccination campaigns targeting millions of children.</p><h3><strong>Epidemiology and Clinical Overview of Measles and Rubella</strong></h3><p>Measles is a highly contagious viral infection transmitted through respiratory droplets when an infected person coughs or sneezes.</p><p>Initial symptoms include fever, cough, and conjunctivitis, often followed by a distinctive rash. Severe complications, including pneumonia, encephalitis, and death, occur primarily in young children or immunocompromised individuals.</p><p>Rubella, also caused by a virus, is generally mild in children and adults. However, maternal infection during pregnancy can result in miscarriage or congenital rubella syndrome, a condition that causes serious birth defects.</p><p>Both diseases spread rapidly in communities with low immunisation coverage. Consequently, they are addressed simultaneously through the combined measles rubella (MR) vaccine.</p><h3><strong>Global Significance of Measles and Rubella in the 2020s</strong></h3><p>Between 2023 and 2025, international health agencies observed a continued rise in measles cases. Factors contributing to this increase included disruptions to routine immunisation during and after the COVID-19 pandemic, conflicts that impeded healthcare delivery, and widespread misinformation about vaccines.</p><p>By late 2025, the World Health Organization (WHO) reported outbreaks across several regions in Africa and Asia. Importantly, these outbreaks reflected gaps in vaccination coverage rather than vaccine inefficacy, highlighting the critical need to maintain high immunisation rates.</p><h3><strong>Mechanisms and Efficacy of Measles Rubella Vaccine</strong></h3><p>The measles-rubella vaccine provides protection against both infections in a single dose or two-dose schedule. Globally, it is one of the most studied vaccines and has been used safely for decades.</p><p><strong>Important considerations in 2026 include</strong>:</p><ul><li>The vaccine is highly safe and effective.</li><li>Two doses confer strong, long-lasting immunity.</li><li>Severe adverse reactions are extremely rare.</li><li>Vaccination contributes to herd immunity, protecting unvaccinated individuals.</li></ul><p>In Nigeria, MR vaccination during public health campaigns typically targets children aged 9 months to 14 years, depending on specific campaign strategies.</p><h3><strong>Nigeria’s National Vaccination Initiative (2025-2026)</strong></h3><p>In late 2025, Nigeria launched one of its largest integrated vaccination campaigns, targeting over 100 million children nationwide. The initiative combined measles-rubella vaccination with other essential child health services to maximize impact.</p><p>This effort is supported by the Federal Government, the National Primary Health Care Development Agency, WHO, UNICEF, Gavi, and other partners. The campaign aims to close immunity gaps accumulated in previous years and prevent future outbreaks. In early 2026, several states reported high coverage rates, vaccinating millions through health facilities, schools, and community outreach programs.</p><h3><strong>Case Study: Ondo State’s Preparatory Measures</strong></h3><p>Ondo State exemplifies proactive planning for measles-rubella vaccination. In 2025, the state government established a technical working group to coordinate logistics, training, and community engagement. Vaccination activities are scheduled to begin in January 2026.</p><p><strong>Preparations include:</strong></p><ul><li>Training health workers</li><li>Strengthening cold chain infrastructure</li><li>Partnering with community leaders to enhance awareness and acceptance</li></ul><p>Additionally, advocacy led by the Ondo State First Lady encouraged parents and caregivers to present eligible children, ensuring readiness ahead of the campaign launch.</p><p><strong>Early Evidence from the Campaign</strong><br>Preliminary reports from other states, such as Nasarawa and Kaduna, indicate measurable progress. Over one million children were vaccinated within short campaign periods. These outcomes are significant because they:</p><p>1. Reduce immediate risk of infection</p><p>2. Prevent future outbreaks</p><p>3. Strengthen public confidence in routine immunisation</p><p>Data collected by the Federal Ministry of Health and partners in early 2026 continue to demonstrate that integrated campaigns improve reach, particularly in underserved communities.</p><h3><strong>Addressing Vaccine Safety and Public Perception</strong></h3><p>Misinformation about vaccine safety persists, though scientific evidence consistently supports the measles rubella vaccine’s safety profile. Nigerian health authorities and international partners, including UNICEF, encourage communities to rely on verified health information and trained professionals. Surveillance systems remain active to monitor adverse events, confirming that serious reactions are rare.</p><h3><strong>Broader Implications for Public Health</strong></h3><p>Nigeria has committed to eliminating measles and rubella by 2030. Achieving this objective requires sustained vaccination coverage, accurate data reporting, and ongoing public trust. Large-scale campaigns in 2026 are not isolated efforts; they reinforce routine immunisation, protect pregnancies, and alleviate the burden on healthcare systems.</p><p>For public health researchers, students, and policymakers, these campaigns show the intersection of policy, community engagement, and evidence-based health delivery in real time.</p><h3><strong>Role of Communities and Families in Vaccination Success</strong></h3><p>Parents and caregivers should ensure that children eligible for vaccination attend designated health facilities, schools, or outreach posts. Community leaders and educators are instrumental in sharing accurate information and supporting healthcare workers. Meanwhile, researchers and advocates can strengthen public health outcomes by documenting results, identifying gaps, and promoting evidence-based communication.</p><h3><strong>Strategic Perspectives on Measles-Rubella Control</strong></h3><p>Measles and rubella remain preventable diseases. Their persistence highlights challenges in access, awareness, and immunisation coverage rather than deficiencies in medical science.</p><p>The vaccination campaigns of 2025-2026 in Nigeria, including the targeted rollout in Ondo State, reflect a deliberate public health strategy to close immunity gaps and prevent outbreaks. Success depends on informed community participation, coordinated health systems, and sustained commitment from policymakers and citizens alike.</p><p>Ultimately, large-scale disease protection is achieved incrementally through each vaccinated child, strengthened health infrastructure, and communities that understand the important role of immunisation in safeguarding public health.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a0b58caa82ca" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Phase 2 Clinical Evaluation of Lassa Fever Vaccines]]></title>
            <link>https://medium.com/@oyinadetokunbo/phase-2-clinical-evaluation-of-lassa-fever-vaccines-d2fd03466c60?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/d2fd03466c60</guid>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[lassa-fever]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Tue, 06 Jan 2026 07:13:43 GMT</pubDate>
            <atom:updated>2026-01-06T07:13:43.876Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*BrJmKknIfABcRVk4CAPQbA.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/photo/lassa-virus-arenavirus-family-single-stranded-rna-virus-gm2193840582-612049211"><em>quantic69</em></a><em> on iStock</em></figcaption></figure><p>Clinical trials are shifting Lassa vaccine research from intent to evidence.</p><p>Lassa fever is still one of the most persistent viral diseases in West Africa. Each year, recurring outbreaks affect thousands of individuals and exert sustained pressure on already strained health systems.</p><p>For many decades, efforts to control the disease depended largely on clinical management, public health education, and attempts to reduce human contact with rodent reservoirs. These approaches, while necessary, were limited by the absence of a licensed vaccine capable of preventing infection.</p><p>This situation is now undergoing a change, such that Lassa fever vaccine research has progressed today, beyond preliminary laboratory work and early safety testing. Active Phase 2 clinical trials are underway within West African countries, led by collaborations that prioritize regional leadership, scientific relevance, and ethical accountability. This development represents a substantive change in how Lassa fever prevention is being approached and warrants close attention.</p><h3><strong>The Scientific Significance of Phase 2 Clinical Trials</strong></h3><p>Phase 2 clinical trials represent a critical stage in vaccine development. At this point, research moves beyond basic safety assessments and begins to evaluate how well a vaccine stimulates immune responses across a broader and more diverse population.</p><p>This stage answers two essential questions. First, does the vaccine maintain an acceptable safety profile when administered to larger groups. Second, does it generate immune responses that are strong and consistent enough to justify progression to trials that measure actual protection against disease.</p><p>The first Phase 2 clinical trial for a Lassa fever vaccine commenced in West Africa in 2024 through a collaboration involving international research organizations, national governments, and regional scientific institutions. Trial sites were established in Nigeria, Ghana, and Liberia, all countries with a history of recurrent outbreaks.</p><p>The inclusion of adults, adolescents, and children reflects the reality that Lassa fever affects people across age groups. This diversity improves the relevance of the data and ensures that findings are grounded in real world exposure patterns rather than theoretical assumptions.</p><p>While these trials do not yet measure protection against infection, they provide the essential evidence required to justify large scale efficacy studies. Without this step, vaccine development cannot proceed responsibly or credibly.</p><h3><strong>The Imperative of Conducting Vaccine Trials Within Endemic Regions</strong></h3><p>Conducting Lassa fever vaccine trials outside West Africa has historically limited scientific and public health progress. Immune responses can vary across populations due to genetic, environmental, and epidemiological factors. Prior exposure to the virus, housing conditions, and patterns of seasonal transmission all influence trial outcomes.</p><p>West Africa offers the epidemiological context necessary for meaningful evaluation of vaccine candidates. Conducting trials within the region also ensures that ethical review processes, regulatory oversight, and community engagement are aligned with local norms and public health priorities.</p><p>Beyond the immediate trials, this work strengthens regional research capacity. Investments in laboratory infrastructure, data management systems, and workforce training will remain in place long after individual studies conclude. These resources will support future outbreak responses and broader public health research efforts.</p><p>This approach reflects practical capacity development achieved through sustained scientific engagement rather than through abstract policy commitments.</p><h3><strong>Integrating One Health Principles Into Vaccine Research</strong></h3><p>Lassa fever cannot be understood solely as a human health issue. Its transmission is closely connected to interactions between people, rodent populations, and environmental conditions.</p><p>A One Health approach to vaccine research acknowledges these connections in practical terms. Trial locations are selected based on known rodent reservoirs and documented outbreak patterns. Environmental factors such as housing quality, food storage practices, and seasonal changes are considered when assessing exposure risk and interpreting study findings.</p><p>Human clinical data is analyzed alongside information about animal reservoirs and environmental conditions. This integrated perspective helps identify where vaccination could have the greatest preventive effect and how immunization strategies might be tailored to specific settings.</p><p>By aligning vaccine research with actual transmission dynamics, this approach supports more informed decision making and improves the likelihood that future vaccination programs will be effective in real world conditions.</p><h3><strong>Ongoing Developments in the Lassa Fever Vaccine Landscape</strong></h3><p>The current Phase 2 trial is part of a broader and increasingly active vaccine research environment. Several additional Lassa fever vaccine candidates, including those based on viral vector technologies, are progressing through earlier stages of testing.</p><p>In late 2025 and moving into 2026, some of these candidates completed Phase 1 safety trials and began preparations for expanded evaluation in West African populations. This diversity of approaches is essential, as no single vaccine platform can be assumed to succeed.</p><p>The presence of multiple candidates increases the likelihood that at least one safe and effective vaccine will emerge. It also encourages scientific rigor and innovation within the field.</p><p>Lassa fever vaccine research has moved beyond stagnation and now reflects sustained and competitive scientific effort.</p><h3><strong>Persistent Challenges in Advancing Vaccine Implementation</strong></h3><p>Despite clear progress, significant challenges remain. Lassa fever outbreaks are often seasonal and unevenly distributed, which complicates the design and execution of efficacy trials. Demonstrating protection against disease requires careful planning and extended observation periods.</p><p>Long term financial support is essential to move vaccine candidates from Phase 2 trials to large scale studies and eventual regulatory approval. Without consistent funding, progress may stall before meaningful public health impact is achieved.</p><p>Equitable access also demands early consideration. A successful vaccine will reduce disease burden only if it reaches populations at highest risk, including rural communities with limited healthcare infrastructure.</p><p>Vaccination must be integrated with existing control measures rather than viewed as a replacement. Rodent control, environmental sanitation, early diagnosis, and clinical management will remain central to reducing transmission and mortality.</p><p><strong><em>The good part here is that,</em></strong><br>Lassa fever vaccine development has reached the most advanced stage in its history. The initiation of Phase 2 clinical trials within West Africa marks a change from conceptual discussion to evidence based progress.</p><p>These trials demonstrate that vaccine research can be designed around the needs and realities of affected populations. The integration of One Health principles further strengthens this effort by ensuring that prevention strategies align with actual patterns of transmission.</p><p>If current trials are successful and sustained investment continues, Lassa fever prevention may finally move beyond reactive containment toward long term reduction. This moment represents not speculation or ambition, but measurable advancement grounded in science, regional leadership, and public health necessity.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d2fd03466c60" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Regional Health Security Through Vaccine Self Reliance]]></title>
            <link>https://medium.com/@oyinadetokunbo/regional-health-security-through-vaccine-self-reliance-a8f113494dfc?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/a8f113494dfc</guid>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[cholera]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Mon, 05 Jan 2026 03:00:09 GMT</pubDate>
            <atom:updated>2026-01-05T03:05:35.064Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZIuIWAy6h0G6xxi6G-TPmw.jpeg" /><figcaption><em>Image by </em><a href="https://www.freepik.com/free-photo/woman-getting-vaccine_15595360.htm#fromView=image_search_similar&amp;page=1&amp;position=0&amp;uuid=d64b2167-651e-4732-8541-5a49b77b33fe"><em>Freepik</em></a></figcaption></figure><h3><strong>Preparedness is the difference between control and crisis.</strong></h3><p>Countries across West Africa and the wider African continent continue to experience recurring outbreaks of vaccine preventable diseases. Cholera remains a persistent public health threat, with repeated outbreaks reported in multiple countries.</p><p>In 2025, public health authorities within the African Union documented thousands of <a href="https://www.aljazeera.com/news/2025/11/13/medical-experts-say-africa-faces-worst-cholera-outbreak-in-25-years#:~:text=The%20Africa%20CDC%20said%20it,logged%20more%20than%207%2C000%20deaths">cholera</a> cases and associated deaths, an outbreak which was described as the continent&#39;s worst in 25 years. In response, political and health leaders across the continent have renewed commitments to eliminate cholera by 2030 while strengthening national and regional response systems.</p><p>Mpox continues to pose a serious challenge to public health. Hundreds of thousands of suspected cases have been reported across Africa. Although coordinated vaccination efforts and improved surveillance have slowed transmission in some settings, the virus remains widespread and continues to strain already stretched health systems.</p><p>At the same time, diseases such as diphtheria and measles are reappearing in communities where immunization coverage has declined or stagnated. Routine immunization rates across the African Region remain below the levels required to prevent outbreaks, leaving many children vulnerable to preventable illness and death.</p><p>Taken together, these trends show the importance of regional health security. Health security depends on the ability of countries to detect disease threats early, respond rapidly, and prevent localized outbreaks from escalating into cross border emergencies. This requires strong systems, trained personnel, adequate resources, and coordinated strategies at national and regional levels.</p><h3><strong>The Importance of Subnational Preparedness in Disease Control</strong></h3><p>Effective preparedness begins at the community level. District and local health teams are often the first to observe unusual patterns of illness. When these teams are able to identify potential outbreaks quickly, report them promptly, and deploy vaccination or treatment responses without delay, disease spread can be contained early. This depends on surveillance systems that function consistently, rather than only during periods of crisis.</p><p>Routine immunization remains one of the most reliable foundations of preparedness. Between 2024 and 2025, vaccine coverage for diseases such as measles, polio, and cervical cancer expanded across parts of Africa, protecting millions of children. Initiatives such as the Big Catch Up campaign reached children who had previously missed routine vaccinations while also strengthening national immunization systems.</p><p>Sustained investment in routine immunization reduces the likelihood of outbreaks and lowers the pressure on emergency response mechanisms. At the subnational level, improvements in vaccine storage, supply chains, and support for community health workers make immunization efforts more effective and resilient over time.</p><h3><strong>Preparedness as a Pillar of Health Security</strong></h3><p>Preparedness enables health systems to act before disease threats escalate into emergencies. Early detection and timely response limit transmission, protect vulnerable populations, and reduce social and economic disruption.</p><p>Preparedness also contributes to public trust. Communities are more likely to participate in vaccination programmes and seek care promptly when they see health systems responding effectively and transparently to outbreaks.</p><p>Because infectious diseases cross borders easily, health security must be understood as a regional responsibility. Information sharing, coordinated preparedness planning, and aligned response strategies reduce the risk that outbreaks in one country will spread unchecked to others.</p><h3><strong>The Strategic Importance of Vaccine Self Reliance</strong></h3><p>Most African countries remain heavily dependent on imported vaccines. Currently, less than one percent of the vaccines used on the continent are manufactured locally. This dependence exposes countries to supply delays and disruptions, particularly during global health emergencies when competition for vaccines intensifies.</p><p>The global financing environment for immunization is also evolving. While international commitments to support vaccine access remain significant, funding gaps and shifting donor priorities have introduced new uncertainties.</p><p>Vaccine self reliance offers a pathway to greater security. Local production capacity allows countries to access critical vaccines when they are needed most, without relying entirely on external supply chains. It also supports the development of research institutions, manufacturing facilities, regulatory systems, and skilled personnel that reflect regional health priorities.</p><h3>Advances in Local Vaccine Manufacturing Capacity</h3><p>In 2025, health ministers and senior officials at the World Health Organization Regional Committee for Africa committed to accelerating local production of vaccines, medicines, and other health technologies. These commitments included expanding clinical trial capacity, strengthening regulatory authorities, and increasing domestic investment in manufacturing.</p><p>A major step forward was the agreement between the World Health Organization Regional Office for Africa and the International Vaccine Institute to support vaccine research and production across the continent. This collaboration focuses on research expansion, technology transfer, regulatory alignment, and workforce development.</p><p>In South Africa, progress was marked by the launch of clinical trials for an oral cholera vaccine manufactured entirely within the country. This achievement demonstrates the growing feasibility of end to end vaccine production in Africa and its potential role in strengthening outbreak response.</p><p>In parallel, regional training networks have been established to build expertise in vaccine research, production, and regulation. These initiatives aim to develop a skilled workforce capable of sustaining vaccine manufacturing over the long term.</p><p>Africa has set a target to produce a substantial share of the vaccines it requires by 2040. Financing mechanisms such as the African Vaccine Manufacturing Accelerator are expected to mobilize significant resources over the coming decade to support this goal.</p><h3><strong>Regional Health Security Considerations for West Africa</strong></h3><p>West African countries are closely interconnected through trade, migration, and social ties. As a result, disease outbreaks rarely remain confined within national borders. An outbreak in one country can quickly affect neighboring states.</p><p>Strengthening regional surveillance systems, coordinating response strategies, and pooling vaccine procurement are essential for protecting the region as a whole. Local vaccine production further enhances national and regional preparedness by reducing delays in access and enabling faster responses to outbreaks that matter most to local populations.</p><p>Equally important is sustained investment in subnational health systems. Empowering local health workers to recognize early warning signs and respond effectively builds confidence in health services and strengthens overall resilience.</p><h3><strong>Priority Actions for Strengthening Health Security and Vaccine Capacity</strong></h3><p>Important actions to enhance subnational preparedness include improving disease surveillance so outbreaks are identified and confirmed quickly, sustaining funding and logistical support for routine immunization, and ensuring that community health workers are adequately trained and integrated into national systems.</p><p>To advance vaccine self reliance, countries should expand infrastructure for research and manufacturing, strengthen and align regulatory systems, invest in workforce training across scientific and public health disciplines, and develop financing mechanisms capable of supporting long term regional production.</p><h3><strong>Sustaining Progress Toward Health Security and Self Reliance</strong></h3><p>Achieving stronger health security and vaccine self reliance requires sustained commitment at all levels, from community clinics to national governments and regional institutions. Preparedness and production are deeply interconnected. A region that can detect disease threats early and produce the vaccines it needs is better equipped to protect its population and safeguard development gains.</p><p>While challenges remain, meaningful progress is already underway. Continued collaboration among communities, health workers, policymakers, and regional partners will be essential. With consistent investment, coordinated action, and clear priorities, Africa can move steadily toward a future in which preventable diseases no longer pose recurring threats and health systems are firmly grounded in regional capacity and resilience.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a8f113494dfc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Occupational Determinants of Welder’s Anthrax Pneumonia]]></title>
            <link>https://medium.com/@oyinadetokunbo/occupational-determinants-of-welders-anthrax-pneumonia-54dece3b56b4?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/54dece3b56b4</guid>
            <category><![CDATA[one-health]]></category>
            <category><![CDATA[infection]]></category>
            <category><![CDATA[anthrax]]></category>
            <category><![CDATA[environment]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Sun, 04 Jan 2026 07:01:39 GMT</pubDate>
            <atom:updated>2026-01-04T07:08:44.282Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vI32SBijCsZTVmV8w-PrHw.jpeg" /><figcaption><em>Image by Freepik</em></figcaption></figure><h3><strong>Routine workplace exposures among welders can precede life-threatening pneumonia.</strong></h3><p>A rare but highly severe form of pneumonia has been identified among welders and other metalworkers in the United States. This illness, commonly referred to as welder’s anthrax, has resulted in multiple fatalities despite its low incidence.</p><p>Although the disease is not caused by the organism responsible for classic anthrax, it involves closely related bacteria capable of producing anthrax toxins. The documented cases have drawn attention to how occupational environments, particularly those involving metal fumes and dust exposure, can increase susceptibility to uncommon but life threatening infections.</p><p>Although 6 of the previous 8 documented US cases have been <a href="https://www.cidrap.umn.edu/anthrax/rare-welder-s-anthrax-case-louisiana-successfully-treated-monoclonal-antibody#:~:text=Welder%27s%20anthrax%20is%20a%20type,US%20cases%20have%20been%20fatal">reported</a> fatal, the severity of outcomes shows the importance of awareness among clinicians, employers, and workers. Welder’s anthrax demonstrates how workplace exposures can interact with environmental pathogens in ways that are not immediately apparent, leading to serious consequences if diagnosis and treatment are delayed.</p><h3>Microbiological Basis of Welder’s Anthrax</h3><p>Welder’s anthrax is not caused by <em>Bacillus anthracis</em>, the organism traditionally associated with anthrax. Instead, it results from infection with members of the <em>Bacillus cereus </em>group that carry genes encoding anthrax toxins. These bacteria are genetically distinct but capable of producing toxins that closely resemble those seen in classic anthrax infections.</p><p>Once inhaled, the bacteria can establish infection in the lungs and release toxins that cause extensive tissue injury. This process leads to rapidly progressive pneumonia, respiratory failure, and systemic illness. The presence of anthrax toxin genes is a defining feature that distinguishes these infections from routine Bacillus cereus pneumonia and explains their unusually severe clinical course.</p><h3><strong>Epidemiology and Documented Cases in the United States</strong></h3><p>The earliest case now recognized as welder’s anthrax occurred in 1994. Between 1994 and 2024, the Centers for Disease Control and Prevention (CDC) confirmed nine cases in the United States. All affected individuals were metalworkers, and the majority were welders. Most cases were identified in the southern United States, particularly in Louisiana and Texas.</p><p>Of the nine documented patients, six died, making the high fatality rate associated with this condition. One widely reported case in 2024 involved an eighteen year old welding apprentice in Louisiana who developed severe pneumonia and respiratory failure. He required mechanical ventilation and intensive care but survived after receiving a combination of antibiotics and the anthrax antitoxin obiltoxaximab.</p><h3><strong>Clinical Presentation and Diagnostic Challenges</strong></h3><p>Patients with welder’s anthrax typically present with symptoms indistinguishable from severe bacterial pneumonia. <br>Common features include;</p><ul><li>Fever</li><li>Cough</li><li>Shortness of breath</li><li>Coughing up blood.</li></ul><p>These symptoms can be mistaken for typical bacterial pneumonia. Chest imaging usually shows abnormal findings consistent with pneumonia but lacks the classic signs associated with inhalation anthrax.</p><p>Because the symptoms overlap with more common respiratory infections, diagnosis can be easily missed. Occupational history is therefore critical. Clinicians must consider welder’s anthrax when a metalworker presents with rapidly worsening pneumonia, especially in regions where previous cases have occurred. Confirmation requires laboratory identification of <em>Bacillus cereus</em> group bacteria along with testing that demonstrates the presence of anthrax toxin genes.</p><h3><strong>Occupational and Environmental Risk Factors</strong></h3><p>Research suggests that several factors increase the risk of welder’s anthrax:</p><ul><li><strong>Metal Fume Exposure on Lung Defense</strong></li></ul><p>Welders are routinely exposed to metal fumes and fine particulate matter such as iron oxide. Long term inhalation of these substances is known to increase the risk of respiratory infections and chronic lung disease. Research suggests that metal particles may interfere with normal immune defenses in the lungs, reducing the ability to clear inhaled bacteria and allowing severe infections to develop.</p><ul><li><strong>Environmental Reservoirs of Causative Bacteria</strong></li></ul><p><em>Bacillus cereus</em> group organisms are commonly found in soil, dust, and other environmental materials. Investigations of welder’s anthrax cases have identified environmental sources near worksites that matched patient isolates. These findings suggest that inhalation of contaminated dust, particularly in settings where soil or debris is disturbed, may play a role in exposure.</p><ul><li><strong>Workplace Conditions and Regional Patterns</strong></li></ul><p>Poorly ventilated workspaces, enclosed welding areas, and tasks that generate high levels of dust may increase inhalation risks. Grinding, cutting, and surface cleaning can all contribute to airborne exposure. Most reported cases have occurred along the Gulf Coast of the United States, but that doesn’t mean the bacteria are limited to this region. They also may exist somewhere else. So. Occupational awareness should not be restricted by geography alone.</p><h3><strong>Diagnostic Approach and Therapeutic Management</strong></h3><p>Early recognition is essential for survival. When welder’s anthrax is suspected, clinicians initiate treatment before laboratory confirmation due to the rapid progression of disease. Management follows principles similar to those used for inhalation anthrax.</p><p>Treatment typically includes broad spectrum intravenous antibiotics and, when available, anthrax antitoxin therapy such as obiltoxaximab. Supportive care in an intensive care setting is often required. Evidence from recent cases indicates that early administration of antitoxin in combination with antibiotics can significantly improve outcomes.</p><h3><strong>Prevention and Occupational Health Implications</strong></h3><p>Reducing risk depends largely on minimizing exposures that compromise lung health. Employers play a central role by ensuring effective ventilation, limiting airborne dust, and enforcing the use of appropriate respiratory protection approved by national safety standards. Worker education is equally important, particularly regarding early symptoms of pneumonia and the need for prompt medical evaluation.</p><p>Welder’s anthrax is a reportable condition in the United States. Ongoing surveillance allows public health authorities to detect patterns, investigate environmental sources, and refine prevention strategies. Clear communication between healthcare providers, workers, and public health agencies remains essential for timely diagnosis and response.</p><p>Welder’s anthrax is an exceptionally rare but highly dangerous occupational illness, and its significance lies not in the number of cases but in the severity of disease and the insight it provides into how workplace exposures can amplify infectious risks. Recognizing welder’s anthrax as an occupational hazard ensures that metalworkers receive appropriate protection and that emerging risks are identified before further lives are lost.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=54dece3b56b4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Avian Influenza Epidemiology and One Health Implications]]></title>
            <link>https://medium.com/@oyinadetokunbo/avian-influenza-epidemiology-and-one-health-implications-703d3c0f67da?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/703d3c0f67da</guid>
            <category><![CDATA[avian-influenza]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[disease]]></category>
            <category><![CDATA[virus]]></category>
            <category><![CDATA[one-health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Sat, 03 Jan 2026 03:40:25 GMT</pubDate>
            <atom:updated>2026-01-03T03:40:25.332Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*wPemdxs11rvB2xa1Vm3fzw.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/photo/the-concept-of-an-avian-flu-pandemic-a-test-tube-with-a-blood-test-for-h5n1-avian-gm2184256360-603099750"><em>Diy13</em></a><em> on iStock</em></figcaption></figure><h3><strong>The evolution of avian influenza demands continuous genomic and epidemiological monitoring.</strong></h3><p><em>Avian influenza</em>, particularly the H5N1 virus, continues to circulate extensively among wild birds, domestic poultry, and some mammal species. Outbreaks are reported in both natural habitats and farming environments, drawing attention to the virus’s adaptability across different animal populations. Recent <a href="https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/#:~:text=The%20ongoing%20threat%20of%20high,livestock%2C%20humans%2C%20and%20regions">detections</a> in mammals, including dairy cattle, demonstrate that the virus can cross species barriers.</p><p>Transmission primarily occurs through migratory birds, which carry the virus along established flyways. Domestic poultry are affected through proximity to wild birds and farm management practices, and infections occasionally reach livestock. These patterns underscore the need for comprehensive monitoring of multiple animal populations to anticipate and control outbreaks.</p><h3><strong>Human Infection Risk and Patterns</strong></h3><p>Human infections with <em>avian influenza</em> remain rare but carry significant health implications. Most cases are associated with direct contact with infected animals, including farm workers, veterinarians, and wildlife handlers. While some new viral strains have been identified in humans, there is currently no evidence of sustained human-to-human transmission.</p><p>Symptoms in infected humans typically involve respiratory illness, and fatalities are limited to a small number of cases. The low general risk to the public allows health agencies to concentrate preventive efforts on high-risk groups, such as individuals with direct animal exposure. Accurate information about these risks is essential to protect vulnerable populations.</p><h3><strong>Viral Evolution and Geographic Spread</strong></h3><p><em>Avian influenza</em> viruses mutate continuously, and the H5N1 lineage currently affecting animals is spreading across multiple regions. Genetic changes in the virus do not automatically indicate a pandemic, but they require ongoing surveillance. Monitoring viral evolution helps identify variants that may increase risks for both animal and human populations, enabling timely interventions.</p><h3><strong>Patterns of Transmission Across Species</strong></h3><p>Wild birds act as reservoirs, facilitating virus spread along migratory routes. Domestic poultry are particularly vulnerable due to close confinement and human activity. Infections in mammals, including livestock, reveal that the virus can affect a wider range of species than previously understood.</p><p>Effective disease monitoring requires attention to all animal populations. Early detection in wild birds, domestic poultry, and livestock supports proactive control measures and reduces the potential for wider outbreaks.</p><h3><strong>Integrated Surveillance and Response</strong></h3><p>Coordinated monitoring of wildlife, livestock, and humans is essential for detecting emerging strains. Field reports, laboratory testing, and genomic sequencing provide the data needed to assess viral behavior. Sharing information across sectors strengthens risk evaluation and allows for timely, targeted interventions.</p><p>Managing outbreaks requires collaboration between agriculture, veterinary, and public health sectors. Veterinary expertise, farm management practices, and occupational safety measures help control infections in animals, while clinical care, laboratory support, and case investigation address human infections. Integrating efforts across these areas ensures that actions in one domain inform decisions in others, enhancing overall outbreak management.</p><h3><strong>Communication and Public Guidance</strong></h3><p>Clear and accurate communication is critical. Workers in agriculture, veterinary services, and wildlife management need practical guidance on protective measures. At the same time, public messaging should convey factual information about risks to prevent misinformation and unnecessary fear. Effective communication supports informed decision-making across communities and sectors.</p><h3><strong>Research Priorities and Preparedness Measures</strong></h3><p>Continuous monitoring of animals and humans is crucial to detect changes in viral behavior early. Rapid information exchange across sectors strengthens response planning and outbreak control. Preparedness strategies, including biosecurity practices on farms, safe handling of animals, and clinical readiness in health facilities, reduce transmission risks and enable timely interventions.</p><p><em>Avian influenza</em> is a significant global concern not because of widespread human transmission but due to its dynamic behavior in animals and potential spillover to humans. Recent human infections highlight the importance of vigilant monitoring, cross-sector cooperation, and evidence-based preventive measures. Sustained surveillance, integrated response efforts, and effective communication are essential to manage the ongoing threat of avian influenza and protect both animal and human populations.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=703d3c0f67da" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Zoonotic Transmission Processes of Marburg Virus Disease]]></title>
            <link>https://medium.com/@oyinadetokunbo/zoonotic-transmission-processes-of-marburg-virus-disease-beb9f98719c2?source=rss-40deeaafab8f------2</link>
            <guid isPermaLink="false">https://medium.com/p/beb9f98719c2</guid>
            <category><![CDATA[marburg]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[disease]]></category>
            <category><![CDATA[one-health]]></category>
            <dc:creator><![CDATA[Oyindamola Adetokunbo]]></dc:creator>
            <pubDate>Sat, 03 Jan 2026 00:59:29 GMT</pubDate>
            <atom:updated>2026-01-03T01:07:20.472Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/612/1*05w_BWPdmGPrcK-VUAbGBQ.jpeg" /><figcaption><em>Photo by </em><a href="https://www.istockphoto.com/photo/marburg-virus-disease-concept-virus-illustration-idea-3d-rendering-gm1467945908-499610127"><em>somboon kaeoboonsong</em></a><em> on iStock</em></figcaption></figure><h3><strong>Marburg virus disease shows how ecological context influences public health risk.</strong></h3><p>Marburg virus disease is often characterized as an acute medical emergency. However, its origins and determinants extend well beyond clinical contexts.</p><p>The virus is embedded within a complex ecological system that connects wildlife reservoirs, human activities, and environmental conditions, underscoring the interconnected nature of disease emergence and transmission.</p><p>In countries such as Ethiopia, where daily life often involves close interaction with natural ecosystems, this interconnectedness is especially relevant. Human exposure to the virus is influenced not only by biology but also by social and environmental factors that shape everyday life.</p><h3><strong>Zoonotic Transmission and Animal Reservoirs</strong></h3><p>Marburg virus disease is a zoonotic infection, meaning that it originates in animals and can be transmitted to humans under certain conditions. Scientific evidence identifies fruit bats, particularly Egyptian fruit bats, as the natural hosts of the virus. These animals can carry the virus without showing signs of illness, allowing it to persist in nature over long periods.</p><p>Human exposure may occur through direct contact with bat secretions, droppings, or saliva, especially in environments where bats roost in large numbers such as caves, mines, and enclosed forest areas. Handling or consuming infected animals can also increase the likelihood of transmission. These interactions are often linked to livelihoods, food practices, or occupational activities rather than deliberate risk taking.</p><p>It is important to emphasize that bats themselves are not the source of the problem. The virus circulates naturally within wildlife populations without human involvement. Infection in humans becomes possible primarily when environmental changes or human activities increase contact. Recognizing this distinction supports rational prevention strategies and avoids fear driven responses that can harm conservation efforts.</p><h3><strong>Pathways of Human Infection and Subsequent Transmission</strong></h3><p>The first human infection usually results from contact with an infected animal or contaminated materials. Once introduced into the human population, the virus spreads through direct contact with blood or other bodily fluids of an infected person.</p><p>Transmission most often occurs in household settings during caregiving, in health facilities where infection prevention measures are insufficient, and during burial practices that involve physical contact with the body. Marburg virus disease is not transmitted through casual contact or through the air.</p><p>Clear and consistent communication about these transmission routes is essential. When communities understand what constitutes risk and what does not, fear is reduced and cooperation with public health measures improves. This clarity strengthens trust and supports effective outbreak response.</p><h3><strong>The Relevance of a One Health Approach in Ethiopia</strong></h3><p>Marburg virus disease lies at the intersection of human health, animal health, and environmental conditions. Addressing only one of these dimensions leaves critical gaps that allow risk to persist. In Ethiopia, where ecological diversity and human reliance on natural resources are central features of daily life, an integrated approach is particularly important.</p><p>A One Health perspective recognizes that wildlife monitoring, environmental management, and public health preparedness are interconnected. Surveillance of bat populations and high risk environments contributes to early warning. Community engagement reduces exposure while respecting livelihoods. Strong and prepared health systems limit the impact of any spillover that may occur.</p><p>Effective prevention and control depend on collaboration across sectors, including public health authorities, veterinary services, environmental agencies, and local communities. No single institution can manage this risk in isolation.</p><h3><strong>Surveillance Systems and Early Detection</strong></h3><p>Early detection is one of the most effective tools for limiting the spread of Marburg virus disease. Surveillance efforts should extend beyond health facilities to include animal health monitoring and community based reporting mechanisms.</p><p>Veterinary professionals, wildlife specialists, and environmental scientists contribute by identifying changes in animal populations or habitats that may signal increased risk. Community health workers play a vital role in recognizing and reporting unusual illnesses at an early stage. Laboratory capacity ensures timely confirmation and guides appropriate response measures.</p><p>Surveillance is not solely about identifying cases. It is about recognizing patterns, understanding vulnerabilities, and intervening before transmission becomes widespread.</p><h3><strong>Human Behavior and Risk Reduction Strategies</strong></h3><p>Patterns of human behavior strongly influence exposure to Marburg virus disease. Activities such as mining, hunting, farming near bat habitats, or entering caves can increase contact with potential animal reservoirs. Reducing risk does not require abandoning these activities, but it does require informed decision making.</p><p>Education initiatives are most effective when they respect local knowledge and focus on everyday practices. Clear explanations of how exposure occurs enable individuals and communities to take practical precautions. Trust between communities and health authorities encourages early reporting and cooperation during response efforts.</p><p>Prevention efforts are strongest when communities are active partners rather than passive recipients of information.</p><h3><strong>Health System Readiness and Response Capacity</strong></h3><p>Health facilities play a central role in limiting human to human transmission. Infection prevention and control practices protect both patients and health workers. Early identification and isolation of suspected cases, appropriate use of protective equipment, and safe handling of biological materials are essential measures.</p><p>Preparedness also depends on training, clear operational protocols, and access to diagnostic services. Health systems that invest in readiness before an outbreak occurs are better positioned to respond effectively and maintain public confidence.</p><p>Preparedness should be understood as an ongoing process that improves through regular assessment and learning rather than as a one time achievement.</p><h3><strong>Regional and Cross Border Dimensions</strong></h3><p>Marburg virus disease does not respect national borders. Human movement, animal migration, and shared ecosystems link Ethiopia with neighboring countries. Regional cooperation strengthens surveillance, information exchange, and response capacity.</p><p>Coordinated planning and data sharing help identify risks early and reduce delays in action. A One Health perspective naturally supports this broader regional outlook by recognizing shared vulnerabilities and responsibilities.</p><p>Marburg virus disease illustrates the close relationship between human health, animal populations, and environmental conditions. In Ethiopia, this relationship is influenced by ecological diversity, livelihood practices, and regional connectivity. Addressing the disease effectively requires making these connections visible and responding to them in a coordinated manner.</p><p>Strengthening surveillance, reducing exposure through informed behavior, supporting community engagement, and maintaining prepared health systems are not separate tasks. Together, they form an integrated approach that reduces risk and builds resilience. A One Health perspective provides a practical and evidence based structure for preventing future outbreaks and protecting both human and ecological well being.</p><p>Education initiatives are most effective when they respect local knowledge and focus on everyday practices. Clear explanations of how exposure occurs enable individuals and communities to take practical precautions. Trust between communities and health authorities encourages early reporting and cooperation during response efforts.</p><p>Prevention efforts are strongest when communities are active partners rather than passive recipients of information.</p><h3><strong>Health System Readiness and Response Capacity</strong></h3><p>Health facilities play a central role in limiting human to human transmission. Infection prevention and control practices protect both patients and health workers. Early identification and isolation of suspected cases, appropriate use of protective equipment, and safe handling of biological materials are essential measures.</p><p>Preparedness also depends on training, clear operational protocols, and access to diagnostic services. Health systems that invest in readiness before an outbreak occurs are better positioned to respond effectively and maintain public confidence.</p><p>Preparedness should be understood as an ongoing process that improves through regular assessment and learning rather than as a one time achievement.</p><h3><strong>Regional and Cross Border Dimensions</strong></h3><p>Marburg virus disease does not respect national borders. Human movement, animal migration, and shared ecosystems link Ethiopia with neighboring countries. Regional cooperation strengthens surveillance, information exchange, and response capacity.</p><p>Coordinated planning and data sharing help identify risks early and reduce delays in action. A One Health perspective naturally supports this broader regional outlook by recognizing shared vulnerabilities and responsibilities.</p><p>Marburg virus disease illustrates the close relationship between human health, animal populations, and environmental conditions. In Ethiopia, this relationship is influenced by ecological diversity, livelihood practices, and regional connectivity. Addressing the disease effectively requires making these connections visible and responding to them in a coordinated manner.</p><p>Strengthening surveillance, reducing exposure through informed behavior, supporting community engagement, and maintaining prepared health systems are not separate tasks. Together, they form an integrated approach that reduces risk and builds resilience. A One Health perspective provides a practical and evidence based structure for preventing future outbreaks and protecting both human and ecological well being.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=beb9f98719c2" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>